Clofazimine broadly inhibits coronaviruses including SARS-CoV-2

文献类型: 外文期刊

第一作者: Yuan, Shuofeng

作者: Yuan, Shuofeng;Chan, Jasper Fuk-Woo;Sze, Kong-Hung;Zhang, Anna Jinxia;Chu, Hin;Kok, Kin-Hang;Chen, Honglin;Yuen, Kwok-Yung;Yuan, Shuofeng;Meng, Xiangzhi;Chan, Jasper Fuk-Woo;Ye, Zi-Wei;Chan, Chris Chun-Yiu;Lai, Pok-Man;Chan, Chris Chung-Sing;Poon, Vincent Kwok-Man;Lee, Andrew Chak-Yiu;Yuen, Chun-Kit;Cao, Jianli;Liang, Ronghui;Tang, Kaiming;Sze, Kong-Hung;Zhang, Anna Jinxia;Chu, Hin;Kok, Kin-Hang;Chen, Honglin;Yuen, Kwok-Yung;Yuan, Shuofeng;Chan, Jasper Fuk-Woo;Yuen, Kwok-Yung;Yin, Xin;Zhang, Yu-Yuan;Tang, Yan-Dong;Cai, Xue-Hui;Yin, Xin;Riva, Laura;Pache, Lars;Matsunaga, Naoko;Pu, Yuan;Chanda, Sumit K.;Chan, Jasper Fuk-Woo;Yuen, Kwok-Yung;Chan, Jasper Fuk-Woo;Yuen, Kwok-Yung;Sheng, Li;Xu, Wan;Lau, Chit-Ying;Jin, Dong-Yan;Sun, Ren;Sheng, Li;Du, Yushen;Sun, Ren;Sit, Ko-Yung;Au, Wing-Kuk;Wang, Runming;Sun, Hongzhe;Clausen, Thomas Mandel;Pihl, Jessica;Oh, Juntaek;Wang, Dong;Esko, Jeffrey D.;Clausen, Thomas Mandel;Pihl, Jessica;Oh, Juntaek;Wang, Dong;Esko, Jeffrey D.;Hung, Ivan Fan-Ngai;Li, Ronald Adolphus;Riva, Laura

作者机构:

期刊名称:NATURE ( 影响因子:42.778; 五年影响因子:46.486 )

ISSN: 0028-0836

年卷期:

页码:

收录情况: SCI

摘要: The COVID-19 pandemic is the third outbreak this century of a zoonotic disease caused by a coronavirus, following the emergence of severe acute respiratory syndrome (SARS) in 2003(1) and Middle East respiratory syndrome (MERS) in 2012(2). Treatment options for coronaviruses are limited. Here we show that clofazimine-an anti-leprosy drug with a favourable safety profile(3)-possesses inhibitory activity against several coronaviruses, and can antagonize the replication of SARS-CoV-2 and MERS-CoV in a range of in vitro systems. We found that this molecule, which has been approved by the US Food and Drug Administration, inhibits cell fusion mediated by the viral spike glycoprotein, as well as activity of the viral helicase. Prophylactic ortherapeutic administration of clofazimine in a hamster model of SARS-CoV-2 pathogenesis led to reduced viral loads in the lung and viral shedding in faeces, and also alleviated the inflammation associated with viral infection. Combinations of clofazimine and remdesivir exhibited antiviral synergy in vitro and in vivo, and restricted viral shedding from the upper respiratory tract. Clofazimine, which is orally bioavailable and comparatively cheap to manufacture, is an attractive clinical candidate for the treatment of outpatients and when combined with remdesivir-in therapy for hospitalized patients with COVID-19, particularly in contexts in which costs are an important factor or specialized medical facilities are limited. Our data provide evidence that clofazimine may have a role in the control of the current pandemic of COVID-19 and-possibly more importantly-in dealing with coronavirus diseases that may emerge in the future.

分类号:

  • 相关文献
作者其他论文 更多>>